These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29988077)

  • 21. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
    Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
    J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
    Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
    J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
    Rowlands CF; Allen S; Balmaña J; Domchek SM; Evans DG; Hanson H; Hoogerbrugge N; James PA; Nathanson KL; Robson M; Tischkowitz M; Foulkes WD; Turnbull C
    Ann Oncol; 2024 Oct; 35(10):892-901. PubMed ID: 38986768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
    Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening Familial Risk for Hereditary Breast and Ovarian Cancer.
    Kiser D; Elhanan G; Bolze A; Neveux I; Schlauch KA; Metcalf WJ; Cirulli ET; McCarthy C; Greenberg LA; Grime S; Blitstein JMS; Plauth W; Grzymski JJ
    JAMA Netw Open; 2024 Sep; 7(9):e2435901. PubMed ID: 39320887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
    Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
    J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome.
    Resch LD; Hotz A; Zimmer AD; Komlosi K; Singh N; Tzschach A; Windfuhr-Blum M; Juhasz-Boess I; Erbes T; Fischer J; Alter S
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
    Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
    Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
    Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.